GLP1R and diabetes mellitus: Liraglutide did not cause symptomatic hypoglycaemia (in a predominantly non-diabetes trial cohort) and significantly reduced weight and stimulated net improvements in lipid profile, in line with the known effects of injectable GLP-1R agonists.